Skip to main content
OpenTrials
Completed

NCT Number: NCT07141472

Glucagon Like Peptide 1 (GLP-1) Booster™ RCT Study

BACKGROUND GLP1 booster (GB) was designed to stimulate the endogenous production of GLP1, which in turn releases insulin, controls blood glucose level, suppresses appetite and thus helps people lose weight.

PURPOSE In prior study, GB was clinically shown to reduce blood sugar level, increase GLP-1 production, and help body fat loss. The purpose of this RCT study is to further assess several clinical endpoints and questionnaires in healthy volunteers taking the new GB formula vs placebo, in the hope of confirming the efficacy and safety of GB.

SCOPE The scope of this protocol covers the non-clinical portion as well as the assessment of several clinical endpoints and questionnaires. In brief, this study is a randomized controlled clinical trial for a total of 26 weeks. Data analysis will involve measuring the clinical endpoints across the group at different timepoints (week 0, 13 and 26).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Blood Sugar; High Body Weight Fat Loss GLP-1 Glucagon Glucose Metabolism Disorders Hyperglycemia Hyperinsulinism Insulin Resistance Metabolic Diseases Nutrition Disorders Nutritional and Metabolic Diseases Obesity Overnutrition Overweight Overweight and Obesity Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Alpine Bio

Salt Lake City, Utah, 84108, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Volunteers must be over the age of 18.
  • Volunteers cannot be smokers.
  • Volunteers cannot be currently taking a dietary supplement or prescription for weight loss.
  • Exercising volunteers must maintain their regimen consistently throughout the course of the 26-week study.
  • Caffeine drinking volunteers must maintain their caffeine intake consistently throughout the course of the 26-week study.
  • Volunteers need to be overweight but not obese, as defined by having a BMI between 25.0 and 29.9

Treatment and study plan

GB

Dietary Supplement

GLP-1 Booster (GB) is a composition designed to increase the endogenous production of GLP-1, improve the activity of GLP-1, enhance the body's response to GLP-1, and thus eventually help people reduce glucose, suppress food intake and lose body fat. GB contains Green tea (Camellia sinensis) leaf extract, Gardeniae (Gardenia jasminoides Ellis) fructus extract, Turmeric (Curcuma longa) root extract, Black pepper (Piper nigrum) extract,Fenugreek (Trigonella foenum-graecum) seed extract, Ginseng (Panax ginseng) root extract, and White kidney bean (Phaseolus vulgaris) extract. Each of these ingredients has been commonly consumed by humans as food sources or supplements and thus has an undebatable safety profile.

Placebo

Dietary Supplement

Placebo is a product that resemble active GB but does not contain any of the active ingredients

Primary outcomes

  1. fasting blood HbA1c level

    Time frame: 26 weeks

    lab

  2. fasting blood glucose level

    Time frame: 26 weeks

    lab

  3. fasting blood insulin level

    Time frame: 26 weeks

    lab

  4. fasting blood GLP-1 level

    Time frame: 26 week

    lab

  5. fasting blood glucagon level

    Time frame: 26 weeks

    lab

  6. fasting blood GIP level

    Time frame: 26 weeks

    lab

  7. fasting blood Amylin level

    Time frame: 26 weeks

    lab

  8. fasting body weight

    Time frame: 26 weeks

    measurement

  9. body fat mass

    Time frame: 26 week

    measurement

  10. waist hip ratio

    Time frame: 26 weeks

    measurement

Secondary outcomes

  1. satiety score

    Time frame: 26 weeks

    questionnaire measuring satiety level from 1 - 10; the higher the score, the more satiety.

  2. resting metabolic rate

    Time frame: 26 weeks

    measurement

  3. Blood pressure

    Time frame: 26 weeks

    both systolic and diastolic pressures

  4. Heart rate

    Time frame: 26 weeks

    measurement

  5. Energy level

    Time frame: 26 weeks

    questionnaire measuring energy level from 1 - 10; the higher the score, the more energy.

Sponsors and collaborators

Lead sponsor

Lawry Han

Industry

Registry information

Official study title

Effects of a Glucagon-like Peptide-1 (GLP-1) Booster™ on Blood Glucose, HbA1c, Insulin, Glucagon, GLP-1, GIP, and Amylin Levels, Body Weight and Body Fat in Overweight Adult Men and Women

Acronym: RCT

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Aug 26, 2025
Registry last updated
Sep 3, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.